drugset / Trial / NCT07668414

A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide

NCT07668414

Phase 3 Not yet recruiting 650 enrolled Novo Nordisk A/S
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to find out if zenagamtide is safe and effective for treating participants who have excess body weight compared to treatment with semaglutide.

Timeline

Start
2026-09-22
Primary completion
2028-10-10
Completion
2028-10-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Semaglutide Peptide Subcutaneous
Subject Zenagamtide Unknown Subcutaneous

Indications